(Q37582918)

21 August 2017

1 reference

title

Emerging drugs for small-cell lung cancer (English)

1 reference

21 August 2017

1 reference

2

1 reference

21 August 2017

1

Giulio Metro

1 reference

21 August 2017

language of work or name

English

0 references

publication date

1 December 2009

1 reference

Expert Opinion on Emerging Drugs

21 August 2017

published in

1 reference

21 August 2017

volume

14

1 reference

21 August 2017

issue

4

1 reference

21 August 2017

page(s)

591-606

1 reference

Going up or coming down? The changing phases of the lung cancer epidemic from 1967 to 1999 in the 15 European Union countries

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728210903206983

Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903206983

Sex differences in lung-cancer risk associated with cigarette smoking.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903206983

Revisions in the International System for Staging Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903206983

The IASLC Lung Cancer Staging Project: data elements for the prospective project

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903206983

Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903206983

Targeting growth factors in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903206983

Randomized Trial of Cyclophosphamide, Doxorubicin, and Vincristine Versus Cisplatin and Etoposide Versus Alternation of These Regimens in Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903206983

Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903206983

Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903206983

Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903206983

Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903206983

Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903206983

A meta-analysis of thoracic radiotherapy for small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903206983

Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903206983

Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903206983

Medical Research Council comparative trial of surgery and radiotherapy for primary treatment of small-celled or oat-celled carcinoma of bronchus. Ten-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903206983

A prospective randomized trial to determine the benefit of surgical resection of residual disease following response of small cell lung cancer to combination chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903206983

Surgical resection of limited disease small cell lung cancer in the new era of platinum chemotherapy: Its time has come.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903206983

Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903206983

Prophylactic cranial irradiation in extensive small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903206983

Predictors of survival following relapse or progression of small cell lung cancer. Southwest Oncology Group Study 8605 report and analysis of recurrent disease data base

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903206983

Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903206983

Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903206983

Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903206983

Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903206983

Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903206983

Phase I-II study of amrubicin and cisplatin in previously untreated patients with extensive-stage small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903206983

Non-cross resistance of ZD0473 in acquired cisplatin-resistant lung cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903206983

ZD0473 treatment in lung cancer: an overview of the clinical trial results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903206983

Phase II study of picoplatin as second-line therapy for patients with small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903206983

Belotecan, new camptothecin analogue, is active in patients with small-cell lung cancer: results of a multicenter early phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903206983

Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903206983

Phase II trial of second-line bendamustine chemotherapy in relapsed small cell lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903206983

Does maintenance/consolidation chemotherapy have a role in the management of small cell lung cancer (SCLC)? A metaanalysis of the published controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903206983

Molecular and biological properties of vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903206983

Small cell lung carcinoma (SCLC): the angiogenic phenomenon

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903206983

Rhebbing up mTOR: New Insights on TSC1 and TSC2, and the Pathogenesis of Tuberous Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903206983

AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903206983

EGFR, HER2 and VEGF pathways: validated targets for cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903206983

TOR, a central controller of cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903206983

A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903206983

Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903206983

The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903206983

The effects of insulin-like growth factors on tumorigenesis and neoplastic growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903206983

Molecular and cellular aspects of the insulin-like growth factor I receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903206983

The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903206983

Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903206983

IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903206983

Potent inhibition of small-cell lung cancer cell growth by simvastatin reveals selective functions of Ras isoforms in growth factor signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903206983

BCL2 family in DNA damage and cell cycle control

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903206983

Upregulation of Bcl-2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903206983

A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903206983

Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903206983

Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903206983

Downstream signalling and specific inhibition of c-MET/HGF pathway in small cell lung cancer: implications for tumour invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903206983

Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903206983

Hedgehog signaling in small-cell lung cancer: frequent in vivo but a rare event in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903206983

Cancer incidence and mortality in Europe, 2004

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903206983

Phase II Trial with Carboplatin and Bendamustine in Patients with Extensive Stage Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903206983

Time Between the First Day of Chemotherapy and the Last Day of Chest Radiation Is the Most Important Predictor of Survival in Limited-Disease Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903206983

Lung Cancer Management in the Asia-Pacific Region: What's the Difference Compared with the United States and Europe? Results of the Second Asia Pacific Lung Cancer Conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903206983

10.1517/14728210903206983

21 January 2018

Identifiers

DOI

1 reference

21 August 2017

1 reference